AstraZeneca

News

Relief for AZ, Amgen as FDA okays severe asthma hope tezepel...

The FDA has approved AstraZeneca and Amgen's severe asthma hope tezepelumab, exonerating the drugmakers' decision to press ahead with a regulatory filing despite a failed phase 3 trial.

News

EU gives narrower label to Apellis, Sobi's PNH drug

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US.

News

AZ's antibody first to be cleared by FDA for COVID preventio...

AstraZeneca's antibody cocktail for COVID-19, now called Evusheld, has become the first drug in the class to be authorised for prevention of infection by the US FDA.

News

AZ, Daiichi take aim at Gilead in triple-negative breast can...

AstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as they build a case to challenge Gilead's already-markete

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6b...

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR).

News

Did AZ scupper Sobi's $8bn private equity buyout?

An $8 billion attempt by two private equity companies to acquire Swedish rare disease specialist Sobi and take it back into private ownership has collapsed, with reports suggesting AstraZen

Relief for AZ, Amgen as FDA okays severe asthma hope tezepel...

EU gives narrower label to Apellis, Sobi's PNH drug

AZ's antibody first to be cleared by FDA for COVID preventio...

AZ, Daiichi take aim at Gilead in triple-negative breast can...

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6b...

Did AZ scupper Sobi's $8bn private equity buyout?

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks